later lines of treatment, including sorafenib and tivozanib for ccRCC and erlotinib for papillary RCC. 20 – 22 Among these, cabozantinib is the only TKI monotherapy listed as a preferred option in the NCCN Guidelines for ccRCC (for intermediate
Search Results
Kelly N. Fitzgerald and Chung-Han Lee
Amanda Bennett, Ronald M. Bukowski, Keith Flaherty, J. Cameron Muir, Craig D. Turner, and Sam Donaldson
18th Annual Conference and was joined in a panel discussion by several of her late husband’s physicians. Mr. Foley’s tumor, variously diagnosed as collecting duct carcinoma and papillary renal cell carcinoma, was an incidental finding in 2000
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Featured Updates to the NCCN Guidelines
Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, and Lisa A. Gurski
should be followed. Treatment of Low-Risk NMIBC By the AUA/SUO risk stratification, low-risk NMIBC includes papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma that is a solitary Ta and ≤3 cm. 3 For these
Letizia Gandolfi, Sarah Adamo, Alessandro Pileri, Alessandro Broccoli, Lisa Argnani, and Pier Luigi Zinzani
BRAF constitutive activation independently of extracellular signals. 15 The BRAF mutation is detected in many malignant diseases, including primary melanoma, hairy cell leukemia, papillary thyroid carcinoma, colorectal cancer, and in approximately
Srinivas K. Tantravahi, and Theresa L. Werner
% to 7% of uterine tumors. 5 Among epithelial tumors, endometrioid histology is the most common subtype, present in 84% of patients. Poor prognostic subtypes, including papillary serous and clear cell carcinomas, represent the other 6%. 6 Risk factors
Presenter: Margaret A. Tempero
as intraductal papillary mucinous neoplasm and mucinous cystic neoplasm…, can transform into what looks exactly like the disease process of the other pathway.” 3 Emergence of Therapeutic Regimens In the phase II/III PRODIGE 4/ACCORD 11 trial
Matthew Zibelman and Elizabeth R. Plimack
papillary, but other subtypes include chromophobe, sarcomatoid, collecting duct, medullary, and various hereditary forms. Patients with metastatic nccRCC have generally demonstrated less responsiveness to the drugs shown to be active in ccRCC. In the TKI era
Keli Turner, Sheelu Varghese, and H. Richard Alexander
illustrate findings that distinguish DMPM from other peritoneal malignancies, whether primary or secondary. Two related primary malignancies of the peritoneum with distinctive characteristics on CT are well-differentiated papillary mesothelioma and
Joshua I. Warrick
Brunn nests, particularly on superficial biopsies. 52 Likewise, the invasive “large nested” variant of UC may appear deceptively similar to non-invasive low-grade papillary UC. 53 No study to the author's knowledge has addressed outcomes in
Donald A. Podoloff, Douglas W. Ball, Edgar Ben-Josef, Al B. Benson III, Steven J. Cohen, R. Edward Coleman, Dominique Delbeke, Maria Ho, David H. Ilson, Gregory P. Kalemkerian, Richard J. Lee, Jay S. Loeffler, Homer A. Macapinlac, Robert J. Morgan Jr., Barry Alan Siegel, Seema Singhal, Douglas S. Tyler, and Richard J. Wong
incidence of thyroid cancer in the United States, 1973–2002 . JAMA 2006 ; 295 : 2164 – 2167 . 151 Albores-Saavedra J Henson DE Glazer E Schwartz AM . Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary
